About Association for Cancer Immunotherapy

The Association for Cancer Immunotherapy (CIMT) is a member-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. Founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine, CIMT operates as an independent non-profit organization and is financed by donations, congress fees, industry sponsorship, and public and foundation grants.

The 14th CIMT annual meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT 2016 is expected to bring together 1,000 international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy. In addition, CIMT unites leading international experts through working groups on immune monitoring, drug development policies, and the translation of scientific knowledge into drug development. This collection hosts posters and slides that were presented at CIMT meetings.